Wednesday May 18 2022
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded nearly $577 million to establish nine Antiviral Drug Discovery Centers (AViDD) for pathogens of pandemic concern.
AViDD Centers will conduct innovative multidisciplinary research to develop candidate COVID-19 antivirals, especially those that can be taken in an outpatient setting, as well as antiviral drugs that target specific viral families with a high potential for causing a future pandemic. These include paramyxoviruses, pannaviruses, togaviruses, filamentous viruses (including Ebola and Marburg viruses), picornaviruses (including enteroviruses and other viruses that cause the common cold), and flaviviruses (including those that cause yellow fever and yellow fever). Dengue and Zika). The awards are part of the Anti-Pandemic Antiviral Program (APP), an intensive research program designed to accelerate the development of treatments for COVID-19. APP is led by NIAID, the National Center for the Advancement of Translational Science (NCATS) and the Office of Research Infrastructure Programs, all of which are part of the National Institutes of Health; and the Biomedical Advanced Research and Development Authority (BARDA), part of HHS.
“The COVID-19 pandemic has highlighted the need for new antiviral drugs, especially those that patients can easily take at home while their symptoms are still mild,” said NIAID Director Anthony S. Fauci, MD, NIAID Anthony Fauci. The structure and vulnerabilities of coronaviruses have greatly accelerated our response to the COVID-19 pandemic, and we hope that similar research focused on antiviral drugs will better prepare us for the next pandemic.”
AViDD centers will conduct research on the early identification and validation of novel viral targets, with a focus on identifying small molecules and biotherapies that directly block viral targets. As candidate drugs are identified and evaluated for properties such as potency and breadth, the most promising drugs will enter a late stage of preclinical development. Most importantly, centers can draw on the resources of their industry partners to accelerate research, leveraging the company’s chemical libraries and expertise to move candidates into the product development pipeline.
AViDD Award recipients are:
- Center for Antiviral Drugs and Epidemic Preparedness
Principal Investigator: Sumit Chanda Ph.D.
Institute: Scripps Research Institute, La Jolla, California
- UTMB-Novartis Alliance for Epidemic Preparedness
Principal investigator: Pei-Yong Shi, Ph.D.
Institute: University of Texas Medical Branch, Galveston
- Rapidly Emerging Antiviral Drug Development Initiative – AViDD . Center
Principal investigator: Ralph Barrick, Ph.D.
Institute: University of North Carolina at Chapel Hill
- Development of outpatient antiviral cocktails against SARS-CoV-2 and other potentially pandemic RNA viruses.
Principal investigator: Jeffrey Glenn, MD, PhD.
Institute: Stanford University School of Medicine, Stanford, California
- Anti-Virus Development Center
Principal Investigators: Ph.D. George Pinter. and Richard Bleiber, Ph.D.
Institutes: Emory University and Georgia State University, Atlanta
- Metropolitan Antiviral Accelerator
Principal investigator: David Perlin, Ph.D.
Institute: Hackensack University Medical Center, Hackensack, New Jersey
- QBI . Corona Virus Research Group’s Pandemic Response Program
Principal investigator: Nevan Krogan, Ph.D.
Institute: University of California, San Francisco
- Midwest Center AViDD
Principal investigator: Robin Harris, Ph.D.
Institute: University of Minnesota, Minneapolis
- AI-powered antivirus platform
Principal Investigators: Ben Perry, Ph.D. Alpha Lee, Ph.D.; John Kodera, Ph.D.
Institutes: Drug Initiative for Neglected Diseases. PostEra Sloan Kettering Institute and Memorial Sloan Kettering Cancer Center, New York City
NIAID conducts and supports research — at the National Institutes of Health, throughout the United States, and around the world — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing, and treating these diseases. Newsletters, fact sheets, and other materials related to NIAID are available on the NIAID website.
About the National Institutes of Health (NIH):
NIH, the country’s medical research agency, includes 27 institutes and centers and is part of the US Department of Health and Human Services. The National Institutes of Health is the primary federal agency that conducts and supports basic, clinical, and polymedical research, investigating the causes, treatments, and treatment of both common and rare diseases. For more information about the National Institutes of Health and its programs, visit www.nih.gov.
National Institutes of Health … Turning Discovery into Health®